John Varga, MD, FACP, MACR
Manage Your Profile
About
John Varga MD attended Columbia University in New York, and obtained his medical degree from New York University. He completed Internal Medicine Residency at Rhode Island Hospital in Providence and Rheumatology Fellowship at Boston University. Following post-doctoral research at the University of Pennsylvania, he was on the faculty of the University of Illinois and Northwestern University in Chicago, and recently was recruited to Chief of Rheumatology at the University of Michigan. For the past three decades, Varga’s research has focused on fibrosis and the application of precision medicine approaches to improve patient outcomes. His lab, continuously funded by the NIH, investigates immunological and cellular mechanisms of fibrosis. He has served as a charter member of the NIH ACTS Study section and Co-Editor of Arthritis and Rheumatology, and is a member of the ACR Board of Directors. He is the author of more than 380 journal articles and book chapters and three textbooks. He has mentored over 20 post-doctoral MD and PhD trainees, many of whom have gone on to develop successful academic or industry careers.
Links
John Varga Sclerolab
Qualifications
-
Post-doctoral Research Fellow, T32University of Pennsylvania, Philadelphia, United States
1985 - 1987
-
Rheumatology FellowBoston University School of Medicine, Boston, United States
1983 - 1985
-
Intern and Resident in MedicineRhode Island Hospital/Brown, United States
1980 - 1983
-
MDNew York University School of Medicine, New York, NY, United States
1978 - 1980
-
BAColumbia University, New York, United States
1971 - 1975
Center Memberships
-
Center MemberSamuel and Jean Frankel Cardiovascular Center
-
Center MemberGlobal REACH
-
Center MemberCenter for Computational Medicine and Bioinformatics
Research Overview
My lab studies inflammation and metabolism in the context of chronic autoimmune and fibrotic diseases. We use mouse models, patient samples, genetics and genomics to identify mechanisms of disease and novel targets for therapy. Our research is patient-oriented and we embrace of a tight "bench-to-bedside-to bench" approach. Our Michigan Scleroderma Program afford unique access to patients including genetics and biological specimen, for our research, including early-stage clinical trials.
Visit the John Varga Sclerolab website: https://medresearch.umich.edu/labs-departments/labs/sclerolab
Recent Publications
-
Verma P, Hamill T, Bale S, Shah K, Patel K, Dey P, Bajzelj M, Yalavarthi B, Tsou P, Gudjonsson JE, Khanna D, Varga J, Bhattacharyya S. Journal of Investigative Dermatology, 2026 Jul 22; 146 (8): s157Journal Article0908 Targeting histone acetyl transferase p300 for treating fibrosis and senescence: A new therapeutic approach
DOI:10.1016/j.jid.2026.06.939 -
Ren H, Verma P, Packiarajan M, Teves M, Varga J. Journal of Investigative Dermatology, 2026 Jul 22; 146 (8): s164Journal Article0952 A novel HDAC6 deacetylase inhibitor elongates primary cilia in fibroblasts: Ciliotherapy for fibrosis
DOI:10.1016/j.jid.2026.06.983 -
Zhang H, Stuart P, Li Q, Patrick M, Varga J, Kahlenberg M, Khanna D, Gudjonsson JE, Tsoi L. Journal of Investigative Dermatology, 2026 Jul 22; 146 (8): s204Journal ArticleLB1169 Genetic risk for systemic sclerosis is mediated through context-dependent regulation of fibroblast inflammatory responses
DOI:10.1016/j.jid.2026.06.1200 -
Nguyen J, Peidl A, Chitturi P, McClintock S, Knibbs R, Kannan Z, Abdi BA, Denomy C, Bhandari P, Carter DE, Petitjean M, Varga J, Khanna D, Stratton RJ, Aslam MN, Varani J, Riser BL, Leask A. 2026 Jul 10; bioRxiv,PreprintCCN3-derived peptide BLR-200 impairs YAP activation and attenuates bleomycin-induced skin fibrosis through blocking the generation of Sfrp2-positive fibroblasts
DOI:10.64898/2026.07.07.734740 -
Ferrant J, Lescoat A, Lecureur V, Lelong M, Varga J, Lafyatis R, Gudjonsson JE, Khanna D. 2026 Jun 7; a29.1 - a2a29.Proceeding / Abstract / PosterOC.28 Skin macrophage subtypes and impact of tofacitinib in early diffuse cutaneous systemic sclerosis: results from combined single-cell analyses of an observational data set and a phase I/II randomized co
DOI:10.1136/jsrd-2026-sswc.28 -
Plazyo O, Dey P, Erba J, Bogle R, Brodie W, Cai A, Tsoi L, Tsou E, Khanna D, Varga J, Gudjonsson J. 2026 Jun 7; a75.1 - a7a75.Proceeding / Abstract / PosterP.019 Collagen VIII: a promising target for anti-fibrotic treatment
DOI:10.1136/jsrd-2026-sswc.73 -
Holm Nielsen S, Tsou P-S, Jamali M, Gudjonsson JE, Huang S, Plazyo O, Bay-Jensen A-C, Varga J, Khanna D. 2026 Jun 7; a237 - a238.Proceeding / Abstract / PosterP.235 Novel biomarkers of type VII collagen turnover are associated with interstitial lung disease and prognostic of pulmonary and skin outcomes
DOI:10.1136/jsrd-2026-sswc.279 -
Holm Nielsen S, Tsou P-S, Jamali M, Gudjonsson JE, Huang S, Plazyo O, Bay-Jensen A-C, Varga J, Khanna D. 2026 Jun 7; a238.1 - a2a238.Proceeding / Abstract / PosterP.236 Biomarkers of fibroblast activity and tissue destruction are associated with diffuse systemic sclerosis, and prognostic of pulmonary and cardiovascular outcomes
DOI:10.1136/jsrd-2026-sswc.280
Featured News & Stories
Compassionate gifts turn heartbreak into hope
Dr. John Varga Honored with Prestigious Lifetime Achievement Award